ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NVTA Invitae Corporation

0.0891
0.00 (0.00%)
Apr 11 2024 - Closed
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Invitae Corporation NVTA NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.0891 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.0891 0.0891
more quote information »

Recent News

Date Time Source Heading
3/06/202408:31EDGAR2Form 8-K - Current report
2/06/202417:07EDGAR2Form 8-K - Current report
1/30/202407:00PRNUSInvitae Partners with BridgeBio Pharma to Harness Genetic..
1/29/202416:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
1/24/202416:34EDGAR2Form 8-K/A - Current report: [Amend]
1/22/202407:05EDGAR2Form 8-K - Current report
1/22/202407:00PRNUSInvitae Completes Sale of Reproductive Health Assets to..
1/18/202416:10EDGAR2Form 8-K - Current report
12/21/202321:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/21/202321:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/14/202316:29EDGAR2Form 8-K - Current report
12/13/202316:07PRNUSInvitae Divests Ciitizen Health Data Platform and Implements..
12/11/202316:41EDGAR2Form 8-K - Current report
11/17/202316:48EDGAR2Form 8-K - Current report
11/15/202316:22EDGAR2Form 8-K - Current report
11/14/202319:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/14/202319:55EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/08/202316:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/08/202316:05EDGAR2Form 8-K - Current report
11/08/202316:01PRNUSInvitae Reports Third Quarter 2023 Financial Results
11/06/202316:00PRNUSInvitae Launches Enhanced Chemistry of MRD Test to Better..
11/01/202306:59PRNUSInvitae to Announce Third Quarter 2023 Financial Results on..
10/25/202311:00PRNUSLandmark Study Reveals Magnitude of Uncertain Results in..
10/20/202318:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/19/202316:38EDGAR2Form 8-K - Current report
10/19/202316:30PRNUSInvitae Appoints Dr. David Sholehvar as Chief Operating..
10/12/202316:15PRNUSRural Hospital System Demonstrates the Clinical Benefits of..
10/10/202316:30PRNUSInvitae to Present Data at the National Society of Genetic..
10/03/202312:07PRNUSInvitae's Common Hereditary Cancers Panel Receives FDA..
10/02/202321:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202320:47EDGAR2Form 3 - Initial statement of beneficial ownership of..
9/29/202320:00DJNFDA Gives Marketing Authorization to Invitae Test for Cancer..
9/27/202316:29EDGAR2Form 8-K - Current report
9/25/202318:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/25/202316:30PRNUSInvitae Announces Appointment of Finance Veteran Ana Schrank..
9/22/202317:02EDGAR2Form 8-K - Current report
9/22/202316:30PRNUSInvitae Receives Notice of Non-Compliance with NYSE Minimum..
9/14/202317:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
8/28/202316:02PRNUSInvitae Hires Industry Veteran Robert Guigley as Chief..
8/23/202308:12EDGAR2Form 8-K - Current report
8/15/202307:30PRNUSClinical Trial Results Support Genetic Testing of All..
8/14/202316:02PRNUSInvitae Announces Selection of Finance Executive Robert..
8/10/202316:03EDGAR2Form 424B2 - Prospectus [Rule 424(b)(2)]
8/10/202316:01EDGAR2Form 424B2 - Prospectus [Rule 424(b)(2)]
8/10/202300:15EDGAR2Form EFFECT - Notice of Effectiveness
8/09/202309:22EDGAR2Form POS AM - Post-Effective amendments for registration..
8/09/202309:20EDGAR2Form POS AM - Post-Effective amendments for registration..
8/08/202316:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/08/202316:09EDGAR2Form 8-K - Current report
8/08/202316:01PRNUSInvitae Reports Second Quarter 2023 Financial Results

Your Recent History

Delayed Upgrade Clock